Trials / Conditions / DLBCL, Nos Genetic Subtypes
DLBCL, Nos Genetic Subtypes
5 registered clinical trials studyying DLBCL, Nos Genetic Subtypes — 3 currently recruiting.
| Status | Trial | Sponsor | Phase |
|---|---|---|---|
| Recruiting | Clinical Study of C402-CD19-CAR Treatment in Subjects With Relapsed or Refractory B-cell Lymphoma NCT06830031 | Shanghai Exuma Biotechnology Ltd. | Phase 1 |
| Recruiting | Epcoritamab (Epcor)-Containing Combination Salvage Therapy Followed by ASCT & Epcor Consolidation in Patients NCT06287398 | Australasian Leukaemia and Lymphoma Group | Phase 2 |
| Active Not Recruiting | Acalabrutinib + Liso-Cel In R/R Aggressive B-Cell Lymphomas NCT05583149 | Patrick C. Johnson, MD | Phase 2 |
| Active Not Recruiting | Study of 19(T2)28z1xx TRAC-Chimeric Antigen Receptor (CAR) T Cells in People With B-Cell Lymphoma NCT05757700 | Memorial Sloan Kettering Cancer Center | Phase 1 |
| Recruiting | Iomab-ACT: A Pilot Study of 131-I Apamistamab Followed by CD19-Targeted CAR T-Cell Therapy for Patients With R NCT04512716 | Memorial Sloan Kettering Cancer Center | EARLY_Phase 1 |